# A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China

> **NCT04825873** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 3102 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04825873
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-28
- **Primary completion:** 2023-02-13
- **Final completion:** 2023-02-13
- **Target enrollment:** 3102 (ACTUAL)
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04825873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04825873, "A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04825873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*